Docket No.

296514US0PCT

IN THE UNITED STATES

RADEMARK OFFICE

IN RE APPLICATION OF:

Kiyoshi OKAMOTO, et al.

SERIAL NO:

10/593,811

GAU:

1632

FILED:

September 22, 2006

EXAMINER:

FOR:

USING NONHUMAN ANIMAL MODEL, METHOD OF MEASURING TRANSCRIPTION ACTIVITY METHOD

OF MEASURING CELL OUANTITY AND METHOD OF MEASURING TUMOR VOLUME

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Customer Number

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

James H. Knebel Registration No. 22,630

ATTY DOCKET NO. SERIAL NO. Form PTO 1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE 296514US0PCT 10/593,811 **APPLICANT** LIST OF REFERENCES CITED BY APPLICANT Kiyoshi OKAMOTO, et al. FILING DATE **GROUP** September 22, 2006 1632 **U.S. PATENT DOCUMENTS** FILING DATE **EXAMINER** DOCUMENT SUB CLASS DATE NAME INITIAL NUMBER CLASS IF APPROPRIATE AA AB AC AD ΑE AF AG AH ΑI ΑJ AK AL ΑM AN FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT DATE COUNTRY NUMBER YES NO WO 03/106663 A1 AO 12/24/2003 WIPO (with English abstract) ΑP AQ AR AS AT OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) K. YAMAGATA, et al., "Experimental study of lymphogenous peritoneal cancer dissemination: migration of fluorescentlabelled tumor cells in a rat model of mesenteric lymph vessel obstruction", JOURNAL OF EXPERIMENTAL CLINICAL CANCER RESEARCH 21, Vol. 19, No. 2, June 2000, 1 page (submitting abstract only). Robert H. SHOEMAKER, et al., "Targeting the HIF-1a Signaling Pathway for Cancer Therapy", THE 7TH INTERNATIONAL SYMPOSIUM ON CANCER CHEMOTHERAPY, December 2-3, 2002, Cover page, pages 2-4 and page 44. Masaki GOTO, et al., "Inhibitory Effect of E3330, a Novel Quinone Derivative Able to Suppress Tumor Necrosis Factor-α AW Generation, on Activation of Nuclear Factor-kB", MOLECULAR PHARMACOLOGY, Vol. 49, No. 5, May 1996, Cover page and pages 860-873. Meng YANG, et al., "A Fluorescent Orthotopic Bone Metastasis Model of Human Prostate Cancer", CANCER RESEARCH. ΑX Vol. 59, No. 4, February 15, 1999, Cover page and pages 781-786. Kristen L. KUCHARCZUK, et al, "Fine-scale transgenic mapping of the MyoD core enhancer: MyoD is regulated by distinct but overlapping mechanisms in myotomal and non-myotomal muscle lineages", DEVELOPMENT, Volume 126, No. 9, May 1999, Cover page and pages 1957-1965. Joseph SAMBROOK, "Protocol 8: Northern Hybridization", MOLECULAR CLONING, A LABORATORY MANUAL THIRD EDITION, 2001, 2 cover ΑZ Additional References sheet(s) attached pages and pages 7.42-7.45. Examiner **Date Considered** *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.